Christoph Mamot

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

Miklos Pless, Roger Stupp, Hans-Beat Ris et al. · The Lancet · 2015 · 380 citations

Medicine, Bronchial Neoplasm, Induction Chemoradiation +7

Epidermal Growth Factor Receptor–Targeted Immunoliposomes Significantly Enhance the Efficacy of Multiple Anticancer Drugs<i>In vivo</i>

Christoph Mamot, Daryl C. Drummond, Charles O. Noble et al. · Cancer Research · 2005 · 379 citations

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

Chulin Sha, Sharon Barrans, Francesco Cucco et al. · Journal of Clinical Oncology · 2018 · 291 citations · Full text

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells

Christoph Mamot, Daryl C. Drummond, Udo Greiser et al. · The Women s Oncology Review · 2004 · 289 citations

Cell-based Drug Delivery, Il Agent, Efficient Drug Delivery +15